Skip to Content

TG Therapeutics Inc TGTX

Morningstar Rating

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire Apr 18, 2024 11:30am
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

GlobeNewswire Apr 18, 2024 11:00am
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire Apr 15, 2024 11:30am
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire Mar 8, 2024 12:30pm
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire Mar 1, 2024 12:30pm
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

GlobeNewswire Feb 28, 2024 12:00pm
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

GlobeNewswire Feb 27, 2024 12:30pm
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

GlobeNewswire Feb 26, 2024 12:00pm
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

GlobeNewswire Feb 23, 2024 12:30pm
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire Feb 20, 2024 12:30pm
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

MarketWatch Jan 10, 2024 12:36pm
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move

MarketWatch Nov 1, 2023 5:55pm
TG Therapeutics' stock rockets after blowout earnings

MarketWatch Nov 1, 2023 2:28pm
TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis

Global News Select Mar 31, 2023 11:59am

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.